• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估一剂 ChAdOx1 nCoV-19(重组)冠状病毒疫苗对三级护理中心住院时间、重症监护病房需求和死亡率结局的影响。

Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre.

机构信息

Department of Ophthalmology, Kusum Dhirajlal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India.

Kusum Dhirajlal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India.

出版信息

Int J Infect Dis. 2021 Dec;113:282-287. doi: 10.1016/j.ijid.2021.10.032. Epub 2021 Oct 21.

DOI:10.1016/j.ijid.2021.10.032
PMID:34688949
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8529545/
Abstract

OBJECTIVE

To comparatively evaluate ICU requirement, length of stay, and mortality between single-dose vaccinated and non-vaccinated hospitalized COVID-19 patients.

DESIGN

A retrospective observational study was carried out in a tertiary care hospital in western Indian, from April 1 to June 30, 2021.

RESULTS

Of the 569 patients who fulfilled the eligibility criteria and were enrolled in the study, 137 (24.08%) patients had received a single dose of ChAdOx1 nCoV-19 vaccine, while 432 (75.92%) patients had not received any form of vaccination. The overall length of stay in hospital was similar for both groups; however, a significant difference was seen in length of stay in the ward and in the ICU. Vaccinated patients were admitted to the ward for 6.21 ± 3.204 days, while non-vaccinated patients were admitted for 5.56 ± 4.55 days (p < 0.001). The mean length of ICU stay for the 21 vaccinated patients requiring intensive care was 4.47 ± 2.3 days, while that for the 145 non-vaccinated patients was 6.29 ± 2.19 days (p < 0.001). Mortality was observed in four patients in the vaccinated group and in 95 patients in the non-vaccinated group.

CONCLUSION

A single dose of ChAdOx1 nCoV-19 vaccine was associated with a significantly lower severity of SARS-CoV-2 infection compared with no vaccination.

摘要

目的

比较评估单剂接种和未接种住院 COVID-19 患者的 ICU 需求、住院时间和死亡率。

设计

这是 2021 年 4 月 1 日至 6 月 30 日在印度西部一家三级护理医院进行的回顾性观察性研究。

结果

符合纳入标准并被纳入研究的 569 名患者中,137 名(24.08%)患者接种了一剂 ChAdOx1 nCoV-19 疫苗,而 432 名(75.92%)患者未接种任何形式的疫苗。两组患者的总体住院时间相似;然而,在病房和 ICU 的住院时间上存在显著差异。接种疫苗的患者在病房的住院时间为 6.21 ± 3.204 天,而未接种疫苗的患者为 5.56 ± 4.55 天(p < 0.001)。21 名需要重症监护的接种患者的 ICU 平均住院时间为 4.47 ± 2.3 天,而 145 名未接种疫苗的患者为 6.29 ± 2.19 天(p < 0.001)。接种组有 4 名患者死亡,未接种组有 95 名患者死亡。

结论

与未接种疫苗相比,一剂 ChAdOx1 nCoV-19 疫苗接种与 SARS-CoV-2 感染的严重程度显著降低相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a954/8529545/d52736b5171e/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a954/8529545/e9e17e88ab8b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a954/8529545/768b9436e46b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a954/8529545/d52736b5171e/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a954/8529545/e9e17e88ab8b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a954/8529545/768b9436e46b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a954/8529545/d52736b5171e/gr3_lrg.jpg

相似文献

1
Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre.评估一剂 ChAdOx1 nCoV-19(重组)冠状病毒疫苗对三级护理中心住院时间、重症监护病房需求和死亡率结局的影响。
Int J Infect Dis. 2021 Dec;113:282-287. doi: 10.1016/j.ijid.2021.10.032. Epub 2021 Oct 21.
2
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.在印度 delta(B.1.617.2)变异株流行期间,ChAdOx1 nCoV-19 疫苗对 SARS-CoV-2 感染的有效性:一项基于病例对照研究的疫苗效力评估和接种后免疫反应的机制研究。
Lancet Infect Dis. 2022 Apr;22(4):473-482. doi: 10.1016/S1473-3099(21)00680-0. Epub 2021 Nov 25.
3
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.新冠病毒疫苗接种后和 SARS-CoV-2 阳性检测后的血小板减少症和血栓栓塞风险:自身对照病例系列研究。
BMJ. 2021 Aug 26;374:n1931. doi: 10.1136/bmj.n1931.
4
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.英格兰长期护理机构居民中 ChAdOx1 nCoV-19 与 BNT162b2 疫苗首针接种对 SARS-CoV-2 感染的疫苗有效性(VIVALDI):一项前瞻性队列研究。
Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23.
5
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19(阿斯利康)疫苗免疫原性和有效性的影响:四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
6
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.英国COVID症状研究应用程序使用者接种疫苗后的疫苗副作用和SARS-CoV-2感染:一项前瞻性观察研究。
Lancet Infect Dis. 2021 Jul;21(7):939-949. doi: 10.1016/S1473-3099(21)00224-3. Epub 2021 Apr 27.
7
Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial).泰国家庭中灭活 SARS-CoV-2 疫苗和 ChAdOx1 nCoV-19 疫苗接种预防 COVID-19 的效果(VacPrevent 试验)。
Int J Infect Dis. 2022 Nov;124:190-198. doi: 10.1016/j.ijid.2022.09.032. Epub 2022 Sep 28.
8
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.《6-17 岁儿童中 ChAdOx1 nCoV-19(AZD1222)疫苗的安全性和免疫原性:COV006 的初步报告,一项 2 期、单盲、随机、对照试验》
Lancet. 2022 Jun 11;399(10342):2212-2225. doi: 10.1016/S0140-6736(22)00770-X.
9
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.腺病毒载体新冠疫苗(ChAdOx1 nCoV-19)对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)的安全性和免疫原性:一项 1/2 期、单盲、随机对照临床试验的初步报告。
Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.
10
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.接种疫苗后 6 个月,由疫苗单独或 SARS-CoV-2 感染加疫苗(混合免疫)诱导的抗体对奥密克戎(B.1.1.529)变异株的中和效果不佳。
EBioMedicine. 2022 Apr;78:103938. doi: 10.1016/j.ebiom.2022.103938. Epub 2022 Mar 16.

引用本文的文献

1
Excretion of SARS-CoV-2 RNA in feces has no prognostic benefit in the outcome of COVID-19: A clinical and immunological study.粪便中 SARS-CoV-2 RNA 的排泄对 COVID-19 的结局没有预后益处:一项临床和免疫学研究。
Biomol Biomed. 2024 Feb 10;24(4):1016-1027. doi: 10.17305/bb.2024.10176.
2
Clinico-pathological study among COVID-19 patients during the second wave of COVID-19 pandemic in Andaman Nicobar Island- "A retrospective cross-sectional study".安达曼-尼科巴群岛第二波新冠疫情期间新冠患者的临床病理研究——“一项回顾性横断面研究”
J Family Med Prim Care. 2022 Nov;11(11):7113-7119. doi: 10.4103/jfmpc.jfmpc_1106_22. Epub 2022 Dec 16.
3

本文引用的文献

1
Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers.医护人员接种ChAdOx1 nCoV-19疫苗后出现的SARS-CoV-2变异株突破性感染
Vaccines (Basel). 2021 Dec 31;10(1):54. doi: 10.3390/vaccines10010054.
2
Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers.健康工作者单次接种 AZD1222/Covishield 疫苗的免疫应答。
Nat Commun. 2021 Jul 29;12(1):4617. doi: 10.1038/s41467-021-24579-7.
3
Implications of the second wave of COVID-19 in India.
Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy.
意大利伦巴第地区 COVID-19 疫苗接种与入住重症监护病房以及 COVID-19 肺炎重症患者结局的相关性。
JAMA Netw Open. 2022 Oct 3;5(10):e2238871. doi: 10.1001/jamanetworkopen.2022.38871.
4
Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients.接种和未接种新冠病毒疫苗的感染患者的临床特征及治疗结果评估
Vaccines (Basel). 2022 Jul 15;10(7):1125. doi: 10.3390/vaccines10071125.
5
Clinical characteristics and respiratory care in hospitalized vaccinated SARS-CoV-2 patients.住院的接种新冠病毒疫苗患者的临床特征及呼吸护理
EClinicalMedicine. 2022 Jun;48:101453. doi: 10.1016/j.eclinm.2022.101453. Epub 2022 May 20.
新冠疫情第二波在印度的影响
Lancet Respir Med. 2021 Sep;9(9):e93-e94. doi: 10.1016/S2213-2600(21)00312-X. Epub 2021 Jun 30.
4
Differences between First wave and Second wave of COVID-19 in India.印度新冠疫情第一波和第二波之间的差异。
Diabetes Metab Syndr. 2021 May-Jun;15(3):1047-1048. doi: 10.1016/j.dsx.2021.05.009. Epub 2021 May 8.
5
Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India.印度新德里一家慢性病医疗保健机构的医护人员和其他工作人员在接种疫苗后突破性感染 COVID19。
Diabetes Metab Syndr. 2021 May-Jun;15(3):1007-1008. doi: 10.1016/j.dsx.2021.05.001. Epub 2021 May 3.
6
India's COVID-19 emergency.印度的新冠疫情紧急情况。
Lancet. 2021 May 8;397(10286):1683. doi: 10.1016/S0140-6736(21)01052-7.
7
Why is India having a covid-19 surge?为什么印度会出现新冠疫情激增的情况?
BMJ. 2021 Apr 30;373:n1124. doi: 10.1136/bmj.n1124.
8
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.苏格兰首次大规模 COVID-19 疫苗接种和 COVID-19 住院的临时发现:一项全国性前瞻性队列研究。
Lancet. 2021 May 1;397(10285):1646-1657. doi: 10.1016/S0140-6736(21)00677-2. Epub 2021 Apr 23.
9
Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.信使 RNA 新冠病毒 2019 疾病(COVID-19)疫苗对医护人员队列中严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的有效性。
Clin Infect Dis. 2021 Sep 15;73(6):e1376-e1379. doi: 10.1093/cid/ciab361.
10
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.单剂 Ad26.COV2.S 疫苗预防新冠病毒的安全性和有效性。
N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21.